



**JONATHAN E. FIELDING, M.D., M.P.H.**  
Director and Health Officer

**JOHN F. SCHUNHOFF, Ph.D.**  
Chief Deputy Director

313 North Figueroa Street, Room 806  
Los Angeles, California 90012  
TEL (213) 240-8156 • FAX (213) 481-2739

[www.lapublichealth.org](http://www.lapublichealth.org)

**BOARD OF SUPERVISORS**

**Gloria Molina**  
First District

**Yvonne B. Burke**  
Second District

**Zev Yaroslavsky**  
Third District

**Don Knabe**  
Fourth District

**Michael D. Antonovich**  
Fifth District

March 13, 2007

The Honorable Board of Supervisors  
County of Los Angeles  
383 Kenneth Hahn Hall of Administration  
500 West Temple Street  
Los Angeles, California 90012

Dear Supervisors:

**HIV EPIDEMIOLOGY PROGRAM COOPERATIVE AGREEMENT  
NO. U62 PS000269-02 FOR THE ENHANCED HIV/AIDS SURVEILLANCE  
PERINATAL PREVENTION PROJECT  
(All Districts) (3 Votes)**

IT IS RECOMMENDED THAT YOUR BOARD:

1. Approve and instruct the Director of Public Health, or his designee, to accept and sign the attached Notice of Grant Award (NGA) No. U62 PS000269-02, (Exhibit I) from the Federal Centers for Disease Control and Prevention (CDC), for Calendar Year (CY) 2007, to support the Enhanced HIV/AIDS Surveillance for Perinatal Prevention project, in the amount of \$106,651, at no net County cost.
2. Delegate authority to the Director of Public Health, or his designee, to accept and sign subsequent NGA's similar to NGA No. U62 PS000269-02 from the CDC, not to exceed 25% of the Calendar Year 2007 award, to support the Enhanced HIV/AIDS Surveillance for Perinatal Prevention project for CY's 2008, 2009, and 2010, upon review and approval of County Counsel and the Chief Administrative Office, and notification to Board offices.
3. Delegate authority to the Director of Public Health, or his designee, to sign amendments to the NGA's from CDC for CY's 2007, 2008, 2009, and 2010 to

accept rollover funds, or to increase or decrease funding up to 25% of each CY's base award, and which do not materially alter the terms and conditions set forth under NGA No. U62 PS000269-02, subject to review and approval of County Counsel and the Chief Administrative Office, and notification to Board offices.

PURPOSE/JUSTIFICATION OF RECOMMENDED ACTION:

Approval of the recommended action will allow the Department of Public Health (DPH or Department) to accept grant funds from CDC to support the Enhanced HIV/AIDS Surveillance for Perinatal Prevention project. Funding will cover expenses related to personnel, operating expenses (including personnel services contract), and indirect cost. The contracted staff, a Medical Records Abstractor, assists the Department's pediatric HIV/AIDS surveillance staff to report prevalent and incident cases of HIV-infected/exposed children diagnosed or delivered at various medical care facilities throughout the County of Los Angeles.

The HIV Epidemiology Program has been collecting continuous surveillance data on all infants identified as born to HIV-infected women in Los Angeles County since 1999. Approval of the recommended actions will allow for the continuation of federally funded HIV/AIDS Surveillance services countywide.

FISCAL IMPACT/FINANCING:

The total program cost for CY 2007 is \$106,651, 100% offset by NGA No. U62 PS000269-02. Funding is included in the FY 2006-07 Adopted Budget and will be requested in future fiscal years. There is no additional net County cost associated with this action.

FACTS AND PROVISIONS/LEGAL REQUIREMENTS:

Since February 1983, the Department has accepted financial assistance from the CDC to support HIV/AIDS Surveillance and Seroprevalence programs.

On December 17, 2002 the HIV Epidemiology Program was awarded funding to support supplemental HIV/AIDS surveillance projects and various subcontracts to conduct HIV/AIDS studies and to provide personnel support services. On subsequent occasions, the Board has accepted additional funding from the CDC for the continuation of these projects. On August 29, 2006, the Board approved NGA No. U62 PS000269-01 from CDC and delegated authority to the Director to accept an NGA for CY 2007 in an amount not to exceed \$100,000 to support the Enhanced HIV/AIDS Surveillance for

The Honorable Board of Supervisors  
March 13, 2007  
Page 3

Perinatal Prevention project. The recommended NGA exceeds the amount authorized by the Board to proceed under the Board's delegated authority.

Attachment A provides additional information. Attachment B is the Grant Management Statement of Grants exceeding \$100,000. Exhibits I and II have been reviewed and approved as to form by County Counsel.

CONTRACTING PROCESS:


It is not appropriate to advertise NGA's on the Los Angeles County Online Web Site as a business/contract opportunity.

IMPACT ON CURRENT SERVICES (OR PROJECTS):

The grant funds will assist the Department in the continuation of HIV/AIDS surveillance activities countywide.

When approved, this Department requires three signed copies of the Board's action.

Respectfully submitted,



Jonathan E. Fielding, M.D., M.P.H.  
Director and Health Officer

JEF:jr  
BL#00079

Attachments (3)

c: Chief Administrator Officer  
County Counsel  
Executive Officer, Board of Supervisors

SUMMARY OF GRANT AWARD

1. TYPE OF SERVICE:

Enhanced HIV/AIDS Surveillance for Perinatal Prevention services. The program will focus on collecting surveillance data on all infants identified as born to HIV-infected women in Los Angeles County.

2. AGENCY ADDRESS AND CONTACT PERSON:

Centers for Disease Control and Prevention  
Acquisition and Assistance Branch I  
Procurement and Grants Officer  
2920 Brandywine Road, Mail Stop E-15  
Atlanta, GA 30341-4146  
Attention: Ms. Angie N. Tuttle, Grants Management Specialist  
Telephone: 404-639-8305 Facsimile (Fax): 404-639-8095  
Electronic Mail: AEN@cdc.gov

3. TERM:

The grant funding period is for Calendar Year 2007.

4. FINANCIAL INFORMATION:

The total program cost for CY 2007 is \$106,651, 100% offset by NGA No. U62 PS000269-02. Funding is included in the FY 2006-07 Adopted Budget and will be requested in future fiscal years. There is no additional net County cost associated with this action.

5. PRIMARY GEOGRAPHIC AREAS TO BE SERVED:

Countywide.

6. ACCOUNTABLE FOR PROGRAM MONITORING AND EVALUATION:

Douglas Frye, M.D., HIV Epidemiology Program.

7. APPROVALS:

Public Health:	John F. Schunhoff, Chief Deputy Director
Contracts and Grants Division:	Gary T. Izumi, Acting Chief
County Counsel (as to form):	Robert Ragland, Senior Deputy County Counsel

BL#00079

JR

## ATTACHMENT B

**Los Angeles County Chief Administrative Office  
Grant Management Statement for Grants Exceeding \$100,000**

Department: \* Public Health


Grant Project Title and Description

**ENHANCED HIV/AIDS SURVEILLANCE PERINATAL PREVENTION PROJECT**

Funding Agency	Program (Fed. Grant #/State Bill or Code #)	Grant Acceptance Deadline
Federal CDC	Notice of Grant Award No. U 62 PS000269-02	ASAP

Total Amount of Grant Funding: \$106,651		County Match Requirements N/A N/A	
Grant Period: CY 2007	Begin Date: January 1, 2007	End Date: December 31, 2007	
Number of Personnel Hired Under this Grant:		Full Time	Part Time
<b><u>Obligations Imposed on the County When the Grant Expires</u></b>			
Will all personnel hired for this program be informed this is a grant funded program?	Yes <u>X</u>	No <u>      </u>	
Will all personnel hired for this program be placed on temporary ("N") items?	Yes <u>X</u>	No <u>      </u>	
Is the County obligated to continue this program after the grant expires	Yes <u>      </u>	No <u>X</u>	
If the County is not obligated to continue this program after the grant expires, the Department will:			
a). Absorb the program cost without reducing other services	Yes <u>      </u>	No <u>X</u>	
b). Identify other revenue sources (Describe)	Yes <u>X</u>	No <u>      </u>	
c). Eliminate or reduce, as appropriate, positions/program costs funded by this grant.	Yes <u>X</u>	No <u>      </u>	
Impact of additional personnel on existing space:		N/A	
Other requirements not mentioned above		N/A	

Department Head Signature



Date 3-1-07

## \*\*\*\*\* NOTICE OF GRANT AWARD \*\*\*\*\*

Issue Date: 12/20/2006

Department of Health and Human Services  
Centers for Disease Control and Prevention


NATIONAL CENTER FOR HIV, VIRAL HEPATITIS, STDs AND TB PREVENTION

Grant Number: 5 U62 PS000269-02

Principal Investigator: FRYE, DOUGLAS M MD

Project Title: PS06-607, Enhanced HIV/AIDS Surveillance for Perinatal Prevention

DIRECTOR, HIV EPIDEMIOLOGY PROGRAM  
LOS ANGELES COUNTY-HIV EPIDEMIOLOGY  
600 S. COMMONWEALTH AVENUE, SUITE 1920  
LOS ANGELES, CA 90005  
UNITED STATES



Budget Period: 01/01/2007 - 12/31/2007

Project Period: 05/01/2006 - 12/31/2008

Dear Business Official:


The Centers for Disease Control and Prevention hereby awards a grant in the amount of \$106,651 (see "Award Calculation" in Section I) to LOS ANGELES COUNTY HEALTH SERVICES DEPT in support of the above referenced project. This award is pursuant to the authority of and is subject to terms and conditions referenced below.

Acceptance of this award including the Terms and Conditions is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Award recipients are responsible for reporting inventions derived or reduced to practice in the performance of work under this grant. Rights to inventions vest with the grantee organization provided certain requirements are met and there is acknowledgement of CDC support. In addition, recipients must ensure that patent and license activities are consistent with their responsibility to make unique research resources developed under this award available to the scientific community, in accordance with CDC policy. For additional information, please visit <http://www.iedison.gov>.

If you have any questions about this award, please contact the individual(s) referenced in the information below.

Sincerely yours,

  
Angie Tuttle

Grants Management Officer

Centers for Disease Control and Prevention

See additional information below

**COPY  
COPY**

SECTION I - AWARD DATA - 5 U62 PS000269-02

AWARD CALCULATION (U.S. Dollars):

Salaries and Wages	\$26,112
Fringe Benefits	\$12,378
Personnel Costs (Subtotal)	\$38,490
Supplies	\$1,000
Travel Costs	\$1,300
Other Costs	\$5,760
Consortium/Contractual Cost	\$53,757
Federal Direct Costs	\$100,307
Federal F&A Costs	\$6,344
APPROVED BUDGET	\$106,651
TOTAL FEDERAL AWARD AMOUNT	\$106,651

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project, is as follows.

03 \$87,906

FISCAL INFORMATION:

CFDA Number: 93.944

EIN: 1956000927A1

Document Number: UPS000269A

IC/ CAN / FY2007 / FY2008  
PS/9212047 / 106,651 / 87,906

ADMINISTRATIVE DATA:

PCC: / OC: 41.41 /Processed: ERAERASERVICES 061220 1125

SECTION II - PAYMENT/HOTLINE INFORMATION - 5 U62 PS000269-02

For payment information see Payment Information section in Additional Terms and Conditions.

To report fraud, waste or abuse see Inspector General section in Additional Terms and Conditions.

SECTION III - TERMS AND CONDITIONS - 5 U62 PS000269-02

This award is based on the application submitted to, and as approved by, the CDC on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- The grant program legislation and program regulation cited in this Notice of Grant Award.
- The restrictions on the expenditure of federal funds in appropriations acts, to the extent those restrictions are pertinent to the award.
- 45 CFR Part 74 or 45 CFR Part 92 as applicable.
- The PHS Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

Treatment of Program Income:

Additional Costs

Funding Opportunity Number (FON): PS06-607

Award Number: U62/PS000269-02

Approval List Number: C0002N07

ADDITIONAL TERMS AND CONDITIONS OF THIS AWARD

Note 1. INCORPORATION: Funding Opportunity Announcement Number PS06-607 entitled, Enhanced Surveillance for Prenatal Prevention; application dated September 29, 2006, and additional requirements, are made a part of this award by reference.

Note 2. INDIRECT COSTS: Indirect costs are approved based on the Indirect Cost Rate Agreement dated May 10, 2006, which calculates indirect costs as 24.2958% of total direct salary costs.

Note 3. RESPONSE TO THE TECHNICAL REVIEW: Attached to this Notice of Award is a Technical Review of the IPR. A list of Action Items can be found on the back of the Technical Review form and at the bottom of each specific section. A response to these action items and any recommendations within the Technical Review must be submitted to the Grants Management Specialist no later than February 1, 2007. Failure to respond to the IPR Technical Review could result in enforcement actions, including withholding of funds or termination.

Note 4. PROGRAM INCOME: Any program income generated under this cooperative agreement will be used in accordance with the additional cost alternative. The disposition of program income must have written prior approval from the Grants Management Officer.

Additional Costs Alternative--Used for costs that are in addition to the allowable costs of the project for any purposes that further the objectives of the legislation under which the cooperative agreement was made. General program income subject to this alternative shall be reported on lines 10r and 10s, as appropriate, of the FSR (Long Form).

Note 5. REPORTING REQUIREMENTS:

a) Final Financial Status Report (FSR, SF 269 or SF 269A): The annual Financial Status Report (FSR) is required and must be submitted 90 days after the end of each budget period. The first year FSR is due to the Grants Management Specialist on March 30, 2007. The reporting period covers May 1, 2006 through December 31, 2006. The FSR should be submitted by your business office on Standard Form 269 and should include only those funds authorized and actually expended during the timeframe covered by the report. Any FSR submitted on a cumulative basis will be returned. If at all possible, do not handwrite forms. Electronic versions of the form can be downloaded into Adobe Acrobat and completed on-line by visiting: <http://www.whitehouse.gov/omb/grants/sf269a.pdf>.

b) Annual Progress Reporting:

i. The interim progress report will serve as your non-competing continuation application. A specific due date and guidance will be provided by the Grants Management Specialist at a later time. The report period covers January 1, 2007, through June 30, 2007. The report must contain the following:

- \* Status/Progress of Current Budget Period Goals and Objectives
  - \* Also include key organizational changes, key staff changes, and an implementation plan for each intervention
  - \* Current Budget Period Financial Progress and amount of estimated unobligated balances
  - \* New Budget Period Program Proposed Activity Objectives and timelines
  - \* Ensure Objectives are specific, measurable, appropriate, realistic, and time-phased
  - \* Measures of Effectiveness
  - \* Additional requested information
  - \* Detailed Line-Item Budget and Justification
  - \* Use the SF424 forms: [http://www.whitehouse.gov/omb/grants/grants\\_forms.html](http://www.whitehouse.gov/omb/grants/grants_forms.html)
- For the Budget details and justification follow the Budget Guidelines shown at:  
<http://www.cdc.gov/od/pgo/funding/grantmain.htm>

ii. The annual progress report d will be due within 90 days from each budget period ending at December 31. The progress reports should cover the period covering January 1 through December 31, 2007. The report should include the following elements:

- a. Detailed description of how each project goal was accomplished or reasons why it was not. Project goals are those that the awardee presented in the original application and those itemized in the RFA, such as:
  - (1) Translating the intervention protocol into everyday language with help from a community advisory board.
  - (2) Drafting an intervention protocol manual, training curricula for agency staff, TA manual and marketing materials.
  - (3) Creating a strategy for publicizing the intervention package, including criteria and process for selecting case study agencies to implement the intervention in Year Two of the project.
  - (4) Developing a plan to help implement the intervention, including training, TA, and procedures for collecting process data.
  - (5) Establishing a plan to evaluate the implementation of the intervention using the package (i.e., cross-site and site-specific process measures and costs).
- b. Results of the replication process evaluation and conclusions:
  - (1) Analysis of all process measures (not summaries) and conclusions.
  - (2) Analysis of costs data, including unit price of the package and itemized and total costs to deliver the intervention.
  - (3) Evaluation of the criteria used to select case study agencies (e.g., the criteria that appear to be essential for an agency's successful replication).
  - (4) Report on the stage of technology transfer (pre-implementation, implementation, maintenance) reached by the case study agencies at the end of the project period.
  - (5) Description of agency feedback and process evaluation results that were incorporated into the refined final package, curricula, and TA guide.
  - (6) Recommendations for tailoring the intervention for agency types and populations other than those for which the intervention was designed.
  - (7) Lessons learned that can inform the translation and dissemination of future REP-packaged interventions.
- c. Six copies of the cleared intervention materials (hard copies and electronic) at the end of the last budget period.

iii. The final progress report is required no later than 90 days after the end of the project period. All manuscripts published as a result of the work supported in part or whole by the cooperative agreement will be submitted with the progress reports.

iv. Reports can be sent electronically; however, an original plus two copies of the progress report must be mailed to the Grants Management Specialist for approval by the Grants Management Officer by the due date noted. Ensure the Award and Program Announcement numbers shown above are on the reports.

Note 6: HIV PROGRAM REVIEW PANEL REQUIREMENT: All written materials, audiovisual materials, pictorials, questionnaires, survey instruments, websites, educational curricula and other relevant program materials have to be reviewed and approved by an established program review panel. A list of reviewed materials and approval dates must be submitted to the CDC Grants Management Specialist.

Note 7: CORRESPONDENCE: ALL correspondence (including emails and faxes) regarding this award must be dated, identified with the AWARD NUMBER as shown at the top right of this page, and include a point of contact (name, phone, fax, and email). All correspondence should be addressed to the Grants Management Specialist listed below:

Angie Tuttle, Grants Management Officer  
Centers for Disease Control, PGO, Branch 1  
2920 Brandywine Road, Mail Stop E-15  
Atlanta, GA 30341-4146

Note 8: PRIOR APPROVAL: All requests, which require prior approval, must bear the signature of an authorized official of the business office of the grantee organization as well as the principal investigator or program or project director named on this notice of award. The request must be postmarked no later than 120 days prior to the end date of the current budget period. Any requests received that reflect only one signature will be returned to the grantee unprocessed. Additionally, any requests involving funding issues must include an itemized budget and a narrative justification of the request.

Prior approval is required but is not limited to the following types of requests: 1) Use of unobligated funds from prior budget period (Carryover); 2) Lift funding restriction, withholding, or disallowance, 3) redirection of funds, 4) Change in Contractor/Consultant; 5) Supplemental funds; 6) Response to Technical Review, or 7) Change in Key Personnel.

Note 9: INVENTIONS: Acceptance of grant funds obligates recipients to comply with the standard patent rights clause in 37 CFR 401.14.

Note 10: CONFERENCE DISCLAIMER AND USE OF LOGOS:

Disclaimer: Where a conference is funded by a grant or cooperative agreement, a subgrant or a contract the recipient must include the following statement on conference materials, including promotional materials, agenda, and Internet sites:

Funding for this conference was made possible (in part) by the cooperative agreement award number above from the Centers for Disease Control and Prevention. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government

Logos: Neither the HHS nor the CDC logo may be displayed if such display would cause confusion as to the source of the conference or give the false appearance of Government endorsement. A non-federal entity's unauthorized use of the HHS name or logo is governed by U.S.C. 1320b-10, which prohibits the misuse of the HHS name and emblem in written

communication. The appropriate use of the HHS logo is subject to the review and approval of the Office of the Assistant Secretary for Public Affairs (OASPA). Moreover, the Office of the Inspector General has authority to impose civil monetary penalties for violations (42 C.F.R. Part 1003). Neither the HHS nor the CDC logo can be used on conference materials, under a grant, cooperative agreement, contract or co-sponsorship agreement without the expressed, written consent of either the Project Officer or the Grants Management Officer. It is the responsibility of the grantee (or recipient of funds under a cooperative agreement) to request consent for the use of the logo in sufficient detail to assure a complete depiction and disclosure of all uses of the Government logos, and to assure that in all cases of the use of Government logos, the written consent of either the Project Officer or the Grants Management Officer has been received.

Note 11: PUBLICATIONS: Publications, journal articles, etc. produced under a CDC grant support project must bear an acknowledgment and disclaimer, as appropriate, such as: This publication (journal article, etc.) was supported by the Grant/Cooperative Agreement Number, as shown at the top right of this page, from CDC. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of CDC.

Note 12: EQUIPMENT AND PRODUCTS: To the greatest extent practicable, all equipment and products purchased with CDC funds should be American-made. CDC defines equipment as Tangible non-expendable personal property (including exempt property) charged directly to an award having a useful life of more than one year AND an acquisition cost of \$5,000 or more per unit. However, consistent with recipient policy, a lower threshold may be established. Please provide the information to the Grants Management Officer to establish a lower equipment threshold to reflect your organization's policy.

Note 13: ACKNOWLEDGMENT OF FEDERAL SUPPORT: When issuing statements, press releases, requests for proposals, bid solicitations and other documents describing projects or programs funded in whole or in part with Federal money, all awardees receiving Federal funds, including and not limited to State and local governments and recipients of Federal research grants, shall clearly state (1) the percentage of the total costs of the program or project which will be financed with Federal money, (2) the dollar amount of Federal funds for the project or program, and (3) percentage and dollar amount of the total costs of the project or program that will be financed by nongovernmental sources.

Note 14: INSPECTOR GENERAL: The HHS Office Inspector General (OIG) maintains a toll-free number (1-800-HHS-TIPS [1-800-447-8477]) for receiving information concerning fraud, waste or abuse under grants and cooperative agreements. Information also may be submitted by e-mail to [hhstips@oig.hhs.gov](mailto:hhstips@oig.hhs.gov) or by mail to Office of the Inspector General, Department of Health and Human Services, Attn: HOTLINE, 330 Independence Ave., SW, Washington DC 20201. Such reports are treated as sensitive material and submitters may decline to give their names if they choose to remain anonymous. This note replaces the Inspector General contact information cited in previous notice of award.

#### Note 15: PAYMENT INFORMATION

##### Automatic Drawdown:

Payment under this award will be made available through the Department of Health and Human Services (HHS) Payment Management System (PMS). PMS is administered by the Division of Payment Management, Program Support Center, HHS. PMS will forward the DHHS Manual for Recipients Financed Under the Payment Management System (PMS), PMS-270 and PMS-272 forms.

##### Telephone Numbers:

Governments (including Tribal) (301) 443-9193; All Others (301) 443-9183

- a.) PMS correspondence, mailed through the U.S. Postal Service, should be addressed as follows: Division of Payment Management, FMS/PSC/HHS, P.O. Box 6021, Rockville, MD 20852.
- b.) If a carrier other than the U.S. Postal Service is used, such as United Parcel Service, Federal Express, or other commercial service, the correspondence should be addressed as follows: Division of Payment Management, FMS/PSC/HHS, Rockwall Building #1, Suite 700, 11400 Rockville Pike, Rockville, MD 20852.

To expedite your first payment from this award, attach a copy of the Notice of Grant/Cooperative Agreement to your payment request form.

Note 16: AUDIT FILING COMPLIANCE: An organization that expends \$500,000 or more in a year in Federal awards shall have a single or program-specific audit conducted for that year in accordance with the provisions of OMB Circular A-133, Audit of States, Local Governments, and Non-Profit Organizations and 45 CFR 74.26, Non-Federal Audits. The audit must be completed along with a data collection form, and the reporting package shall be submitted within the earlier of 30 days after receipt of the auditor's report(s), or nine months after the end of the audit period.

\*\*The audit report must be sent to: Federal Audit Clearinghouse, 1201 E. 10th Street, Jeffersonville, IN 47132

For Form SF-SAC and A-133 Submission Questions, visit:

<http://harvester.census.gov/sac/FACCONTA.htm> or contact the Federal Audit Clearinghouse by email, phone, or fax.

[govs.fac@census.gov](mailto:govs.fac@census.gov)

(301) 763-1551 (voice)

(800) 253-0696 (toll free)

(301) 457-1592 (fax)

The grantee is to ensure that the sub-recipients receiving CDC funds also meet these requirements (if total Federal grant or cooperative agreement funds received exceed \$500,000). The grantee must also ensure that appropriate corrective action is taken within six months after receipt of the sub-recipient audit report in instances of non-compliance with Federal law and regulations. The grantee is to consider whether sub-recipient audits necessitate adjustment of the grantee's own accounting records. If a sub-recipient is not required to have a program-specific audit, the Grantee is still required to perform adequate monitoring of sub-recipient activities. The grantee is to require each sub-recipient to permit independent auditors to have access to the sub-recipient's records and financial statements. The grantee should include this requirement in all sub-recipient contracts.

Note 17. KEY PERSONNEL: In accordance with 45 CFR Part 92, CDC recipients shall obtain prior approvals from CDC for (1) Change in the project director or principal investigator or other key persons specified in the application or award document, and (2) the absence for more than three months, or a 25 percent reduction in time devoted to the project, by the approved project director or principal investigator.

Note 18. CDC CONTACT NAMES:

Business and Grants Policy Contact

Angie Tuttle, Grants Management Officer

Centers for Disease Control, PGO, Branch I

2920 Brandywine Road, Mail Stop E-15

Atlanta, GA 30341-4146  
Telephone: (404) 639-8305  
Fax: (404) 639-8095  
Email: aen4@cdc.gov

Programmatic and Technical Contacts:

Donald Mixon, Project Officer  
Centers for Disease Control and Prevention  
Division of HIV/AIDS Prevention  
8 Corporate Blvd, Mail Stop E-37  
Atlanta, GA 30329  
Telephone: (404) 639- 4108  
Fax: (404) 639-2980  
Email: DMixon@cdc.gov

Angie Tuttle, Grants Specialist

Phone: (404) 639-8305 Email: atuttle@cdc.gov Fax: (404) 639-8095

SPREADSHEET

GRANT NUMBER: 5 U62 PS000269-02

P.I.: FRYE, DOUGLAS M

INSTITUTION: LOS ANGELES COUNTY HEALTH SERVICES DEPT

	YEAR 02	YEAR 03
	=====	=====
Salaries and Wages	26,112	15,508
Fringe Benefits	12,378	6,792
Personnel Costs (Subtotal)	38,490	22,300
Supplies	1,000	1,000
Travel Costs	1,300	
Other Costs	5,760	5,808
Consortium/Contractual Cost	53,757	55,204
TOTAL FEDERAL DC	100,307	84,312
TOTAL FEDERAL F&A	6,344	3,594
TOTAL COST	106,651	87,906

**EXHIBIT II****COUNTY OF LOS ANGELES - DEPARTMENT OF PUBLIC HEALTH  
HIV EPIDEMIOLOGY PROGRAM****U62/PS000269-02****ENHANCED SURVEILLANCE FOR PERINATAL PREVENTION****January 1, 2007 - December 31, 2007**

	<b>Annual Salary</b>	<b>Monthly Salary</b>	<b># of Pos</b>	<b>% of Time</b>	<b># of Mos</b>	<b>Total Budget</b>
<b>I. PERSONNEL</b>						
Sr. Physician						
Douglas Frye, M.D.*	\$148,968	\$12,414	1	1%	12	\$1,490
Epidemiologist						
Azita Naghdi *	\$72,396	\$6,033	1	20%	12	\$14,479
Data Conv. Supe. I						
Mary Vitale	\$40,572	\$3,381	\$1	25%	12	\$10,143
Total Salaries						\$26,112
Employee Benefits @ 47.4026%						\$12,378
Total Personnel						\$38,490
<b>II OPERATING EXPENSES</b>						
Office Supplies						\$1,000
Travel						\$1,300
Space						\$5,760
Contractual:						
Personnel Services Contract						\$53,757
Total Operating Expenses						\$61,817
<b>III. INDIRECT COST @ 24.2958% of total salaries</b>						\$6,344
<b>IV. TOTAL REQUEST</b>						<b>\$106,651</b>

\* Key Personnel Item